Clinical trials: Diabetic Nephropathy.
Diabetic Kidney Disease
Oxygen Therapy in Diabetic Kidney Disease
Diabetic kidney disease (DKD) is the most significant cause of end-stage kidney disease (ESKD). Albuminuria, evolving from microalbuminuria to nephrotic-range proteinuria, is a clinical hallmark of diabetic nephropathy (DN).
- Trial name
- NCT06959485
- Testing
- Oxygen Therapy
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
Chronic Kidney Disease, Diabetic Kidney Disease
"Residual Kidney Function and Oxidative Stress in Incremental vs Standard Peritoneal Dialysis (2 Mexican Centers)"
Title: Comparison of Oxidative Stress and Preservation of Residual Kidney Function Between Incremental and Standard Peritoneal Dialysis in Incident Patients at the Regional General Hospital No.
- Conditions
- Chronic Kidney Disease, Diabetic Kidney Disease, Peritoneal Dialysis (PD), Hypertension
- Trial name
- INSPiRE (NCT07338435)
- Testing
- Standard Peritoneal Dialysis, Incremental Peritonal Dialysis
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Instituto Mexicano del Seguro Social
Diabetic Kidney Disease, Diabetic Nephropathies
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
The Researchers will assess the safety, tolerability, dosing effect, and early signals of efficacy of intra-arterially delivered autologous (from self) adipose (fat) tissue-derived mesenchymal stem/stromal cells (MSC) in patients…
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT03840343
- Testing
- Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose, Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Diabetes Mellitus, Type I, Diabetic Nephropathy
Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease
The primary aim is to evaluate the anti proteinuric effect of increasing doses of the ACE inhibitor, lisinopril: 20, 40 and 60 mg daily in type 1 diabetic patients with hypertension and diabetic nephropathy.
- Trial name
- NCT00118976
- Testing
- Lisinopril
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Steno Diabetes Center Copenhagen
Diabetic Nephropathy Type 2
Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.
The main purpose of this study is to explore the improvement of renal function before and after the intervention of dorzagliatin in patients with type 2 diabetes.
- Trial name
- NCT06222476
- Testing
- Dorzagliatin, Gliclazide
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Yan Bi
Diabetic Nephropathy
An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy
It is well understood that hypertension, dyslipidemia, and diabetes mellitus are the major risks of chronic kidney disease. Current guidelines recommend screening kidney estimated glomerular filtration function with serum…
- Trial name
- NCT01273675
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Diabetes Mellitus, Diabetic Nephropathy
Estimation of Glomerular Filtration Rate (GFR) in Patients With Type 2 Diabetes Mellitus.
The purpose of the present study is to evaluate bias, precision and accuracy of new cystatin C and creatinine based equations for GFR estimation compared with 51Cr-EDTA (chromium-51 labeled ethylenediamine tetraacetic acid)…
- Trial name
- NCT01215994
- Where
- Greece
- Volunteers
- 600 people
- Sponsor
- AHEPA University Hospital
Diabetes Mellitus, Type 2, Diabetic Nephropathy
Enhancing Adherence in Type 2 Diabetes: The ENHANCE Study
This randomized study will test a behavioral intervention, based on social cognitive theory (SCT), to improve regimen adherence in three different groups of people with type 2 diabetes; (1) those with well controlled blood…
- Trial name
- ENHANCE (NCT00222846)
- Testing
- Attention control, Intervention
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- University of Pittsburgh
Diabetes Mellitus, Impaired Renal Function
Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment
The purpose of this study is compare the effects of simvastatin+ezetimibe with those of simvastatin alone on platelet activity, platelet-leukocyte interactions and inflammatory variables in diabetic patients with or without…
- Trial name
- PLAUDIT (NCT01035320)
- Testing
- Ezetimibe
- Where
- Sweden
- Volunteers
- 39 people
- Sponsor
- Karolinska Institutet
Proteinuria, Kidney Dysfunction
Azilsartan in Patients With Diabetic Kidney Disease and Hypertension
Hypertension is the most common complication in patients with diabetes nephropathy. Strengthening blood pressure and blood sugar control is the basic treatment for patients with diabetes nephropathy.
- Conditions
- Proteinuria, Kidney Dysfunction, Blood Pressure, Diabetic Kidney Disease
- Trial name
- NCT05753696
- Testing
- Azilsartan, Losartan
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diabetic Kidney Disease, Type 2 Diabetes
Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care
Type 2 diabetes is the leading cause of chronic kidney disease, which can result in serious complications such as kidney failure and heart disease.
- Conditions
- Diabetic Kidney Disease, Type 2 Diabetes, Chronic Kidney Disease
- Trial name
- RX4DKD (NCT07169422)
- Testing
- Usual care for diabetic kidney disease management without primary care provider., Pharmacist-led validated diabetic kidney disease decision support algorithm.
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Nova Scotia Health Authority
Type 2 Diabetes, Diabetic Nephropathy
Role of Sleep Apnea and Sympathetic Activity in Resistant Hypertensive Patients.
Hypertension is highly prevalent in type 2 diabetic patients (NIDDM) with nephropathy, and is the single most important determinant of the rate of renal function loss.
- Conditions
- Type 2 Diabetes, Diabetic Nephropathy, Hypertension, Sleep Apnea
- Trial name
- SAS (NCT01875341)
- Testing
- NCPAP; Nasal continuous positive airway pressure., NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Ottawa Hospital Research Institute
Diabetic Nephropathies
Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients
Diabetes Mellitus is the leading cause of end stage renal disease. As proven by many studies , controlling proteinuria can delay the progression to end stage renal disease.This work will study the effect of sodium glucose co…
- Trial name
- NCT03573102
- Testing
- SGLT2 inhibitor, ACE inhibitor
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Nahla H Tohami
Diabetes Mellitus, Type 1, Nephropathy
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
Over 1.25 million Americans have type 1 diabetes (T1D), increasing risk for early death from cardiorenal disease. The strongest risk factor for cardiovascular disease (CVD) and mortality in T1D is diabetic kidney disease (DKD).
- Conditions
- Diabetes Mellitus, Type 1, Nephropathy, Diabetic Nephropathies, Juvenile Diabetes
- Trial name
- CASPER (NCT03618420)
- Testing
- Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Colorado, Denver
Diabetic Kidney Disease, Type 1 Diabetes
Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes
Diabetic kidney disease (DKD) is a leading cause of chronic and end-stage kidney disease, affecting 25-40% of type 1 diabetes (T1D) patients and 5-40% of type 2 diabetes (T2D) patients.
- Trial name
- NCT06532682
- Testing
- dapagliflozin, ACE inhibitor
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Chronic Kidney Diseases, Diabetes Mellitus, Type 2
Stem Cell Therapy for Chronic Kidney Disease
The purpose of this study is to assess the safety and tolerability of allogeneic mesenchymal stem / stromal cell therapy in individuals with chronic kidney disease.
- Conditions
- Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus
- Trial name
- NCT04869761
- Testing
- Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- LaTonya J. Hickson
Chronic Kidney Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV)…
- Trial name
- NCT07024823
- Testing
- AZD4248
- Where
- 5 sites in United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetic Nephropathy Type 2, Chronic Renal Failure/ Kidney Disease
Research on Innovative Traditional Chinese Medicine Diagnosis and Treatment Technologies for Diabetic Nephropathy Driven by Multi-Omics and Artificial Intelligence
With the help of the 'Traditional Chinese Medicine Specialty Alliance Platform-Multicenter RCT Clinical Research Database,' this platform can be used to conduct scientific research on various aspects of DKD, such as disease…
- Trial name
- NCT07459946
- Testing
- Jiajian Yishen Xiaozheng Qufeng Granules
- Volunteers
- 198 people
- Sponsor
- Jiazhen Yin